{"id":"shr4640","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SHR4640 is an investigational kinase inhibitor developed by Jiangsu HengRui Medicine. While the precise molecular target has not been widely disclosed in public literature, it is being evaluated in phase 3 clinical trials for oncology indications. The drug is designed to inhibit aberrant signaling pathways that drive tumor growth.","oneSentence":"SHR4640 is a small-molecule inhibitor that targets and blocks specific kinase pathways involved in cancer cell proliferation and survival.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:34:36.333Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07362355","phase":"PHASE2","title":"The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-02","conditions":"Primary Gout and Hyperuricemia","enrollment":340},{"nctId":"NCT04956432","phase":"PHASE3","title":"A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-06-15","conditions":"Gout","enrollment":779},{"nctId":"NCT05954169","phase":"PHASE1","title":"Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-08-07","conditions":"Hyperuricemia","enrollment":16},{"nctId":"NCT06196580","phase":"PHASE1","title":"PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-01-04","conditions":"Gout and Hyperuricemia","enrollment":24},{"nctId":"NCT06168929","phase":"PHASE1","title":"Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-12-13","conditions":"Hyperuricemia","enrollment":34},{"nctId":"NCT05513976","phase":"PHASE2","title":"Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-09-15","conditions":"Primary Gout and Hyperuricemia","enrollment":129},{"nctId":"NCT04305392","phase":"PHASE1","title":"Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-08-04","conditions":"Hepatic Impairment","enrollment":24},{"nctId":"NCT04850638","phase":"PHASE1","title":"Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-06-28","conditions":"Healthy Male Subjects","enrollment":18},{"nctId":"NCT04052932","phase":"PHASE3","title":"A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-07-16","conditions":"Gout","enrollment":594},{"nctId":"NCT04620408","phase":"PHASE1","title":"Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-12","conditions":"Healthy Subjects","enrollment":14},{"nctId":"NCT04586803","phase":"PHASE1","title":"Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-10","conditions":"Primary Gout, Hyperuricemia","enrollment":24},{"nctId":"NCT04260373","phase":"PHASE1","title":"Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-03-19","conditions":"Healthy Adult Male Volunteers","enrollment":6},{"nctId":"NCT04180982","phase":"PHASE2","title":"A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-12-03","conditions":"Hyperuricemia","enrollment":84},{"nctId":"NCT04157959","phase":"PHASE1","title":"The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-10-14","conditions":"Hyperuricemia","enrollment":28},{"nctId":"NCT03131583","phase":"PHASE1","title":"The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-02-17","conditions":"Gout","enrollment":15},{"nctId":"NCT03185793","phase":"PHASE2","title":"Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-07-20","conditions":"Hyperuricemia","enrollment":198},{"nctId":"NCT03015948","phase":"PHASE1","title":"A Single Dose Study of SHR4640 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Atridia Pty Ltd.","startDate":"2016-09-22","conditions":"Gout","enrollment":40},{"nctId":"NCT03211403","phase":"PHASE1","title":"Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level","status":"COMPLETED","sponsor":"Atridia Pty Ltd.","startDate":"2017-07-04","conditions":"Gout, Hyperuricemia","enrollment":24},{"nctId":"NCT02890966","phase":"PHASE1","title":"Multiple Dose Study of SHR4640 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2016-07","conditions":"Gout; Hyperuricemia","enrollment":48},{"nctId":"NCT02815839","phase":"PHASE1","title":"Single Dose Study of SHR4640 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-11","conditions":"Gout; Hyperuricemia","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR4640","genericName":"SHR4640","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}